Profitability Ratios
| Ratio |
Value |
| GP Margin |
100.0% |
| EBIT Margin |
-326.6% |
| EBITDA Margin |
-316.5% |
| Operating Margin |
-326.6% |
| Pretax Margin |
-296.2% |
| Cont. Ops Margin |
-296.5% |
| Net Margin |
-296.5% |
| Bottom Line Margin |
-296.5% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
7.64 |
| Quick Ratio |
7.64 |
| Solvency Ratio |
-2.058 |
| Cash Ratio |
2.46 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.02 |
| Forward PEG |
-0.02 |
| Price/Book |
1.18 |
| Price/Sales |
5.71 |
| Price/FCF |
-1.71 |
| Price/Op Cash Flow |
-1.74 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.1447 |
| Debt/Equity |
0.1861 |
| Debt/Capital |
0.1569 |
| Long-Term Debt/Capital |
0.0000 |
| Financial Leverage |
1.29 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.20 |
| Operating Cash Flow Ratio |
-4.991 |
| Operating Cash Flow/Sales |
-328.1% |
| Free Cash Flow/Operating Cash Flow |
102.0% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-16.32 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
-16.90 |
| Operating Cash Flow Coverage |
-3.63 |
| Capital Expenditure Coverage |
-51.03 |
| Dividend + Capital Expenditure Coverage |
-51.03 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.69 |
| EPS |
-2.040 |
| Debt/Share |
0.6219 |
| Cash/Share |
3.35 |
| Book Value/Share |
3.34 |
| Tangible BV/Share |
3.34 |
| Equity/Share |
3.34 |
| Operating Cash Flow/Share |
-2.257 |
| Capital Expenditure/Share |
0.044 |
| FCF/Share |
-2.301 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.001 |
| Earnings Before Tax/EBIT |
0.907 |
| Price/Fair Value |
1.18 |
| Debt/Market Cap |
0.0340 |
| Effective Tax Rate |
-0.1% |
| Enterprise Value Multiple |
-1.58 |
VYGR - Voyager Therapeutics, Inc.